Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Non-cash Items (2016 - 2019)

Historic Non-cash Items for Neurocrine Biosciences (NBIX) over the last 8 years, with Q4 2019 value amounting to $4.0 million.

  • Neurocrine Biosciences' Non-cash Items rose 256.41% to $4.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was $4.0 million, marking a year-over-year increase of 256.41%. This contributed to the annual value of $4.0 million for FY2019, which is 256.41% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Non-cash Items of $4.0 million as of Q4 2019, which was up 256.41% from $3.9 million recorded in Q4 2018.
  • Neurocrine Biosciences' 5-year Non-cash Items high stood at $4.5 million for Q4 2016, and its period low was $3.8 million during Q4 2015.
  • For the 5-year period, Neurocrine Biosciences' Non-cash Items averaged around $4.1 million, with its median value being $4.0 million (2019).
  • In the last 5 years, Neurocrine Biosciences' Non-cash Items plummeted by 952.38% in 2015 and then surged by 1842.11% in 2016.
  • Quarter analysis of 5 years shows Neurocrine Biosciences' Non-cash Items stood at $3.8 million in 2015, then increased by 18.42% to $4.5 million in 2016, then decreased by 6.67% to $4.2 million in 2017, then fell by 7.14% to $3.9 million in 2018, then rose by 2.56% to $4.0 million in 2019.
  • Its last three reported values are $4.0 million in Q4 2019, $3.9 million for Q4 2018, and $4.2 million during Q4 2017.